RLMD
Relmada Therapeutics Inc
3.50$
-3.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -10.6% | -13.5% | -15.9% | -21.5% | -17.8% | -39.6% | -23.7% | -29.6% | +531.9% | +150.4% | -6.9% | |
| – | -10.6% | -13.5% | -15.9% | -21.5% | -17.8% | -39.6% | -23.7% | -29.6% | +532.7% | +150.4% | -6.9% | |
| – | -38.9% | -67.4% | +56.3% | -28.9% | +159.9% | -70.2% | +17.7% | +2.3% | +152.6% | +179.6% | +15.9% | |
| – | -9.4% | -13.2% | -15.8% | -23.2% | -17.0% | -39.7% | -23.8% | -32.7% | +569.8% | +151.6% | -6.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +44.8% | +1.4% | -22.9% | -15.1% | +27.1% | -49.1% | -1.4% | +4.7% | +38.5% | +122.0% | -24.8% | |
| – | +44.8% | +1.4% | -22.9% | -15.2% | +27.3% | -49.2% | -1.9% | +1.1% | +23.9% | +100.5% | -42.4% | |
| – | +22.7% | +48.0% | -19.6% | -43.8% | +76.1% | -69.4% | +7.7% | +6.7% | +8.0% | +265.3% | -58.0% | |
| – | -15.3% | -15.6% | -14.6% | -22.6% | -25.4% | -36.8% | -28.9% | -40.7% | +814.0% | +152.8% | -5.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.1% | +0.1% | +0.0% | +0.0% | +0.8% | +9.2% | +0.0% | +105.6% | +26.9% | +29.8% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.